Target intelligence / Profile preview

Interleukin 1 beta mRNA 3'-untranslated region (IL1B mRNA 3'-UTR)

Target
IL1B mRNA 3'-UTR
Molecular classification
RNA, Untranslated region (UTR)
01

Overview

The Interleukin 1 beta (IL1B) mRNA 3'-untranslated region (3'-UTR) is a critical regulatory segment of the IL1B transcript that controls the stability and translation of this potent pro-inflammatory cytokine. It contains several conserved motifs, including AU-rich elements (AREs), which serve as binding sites for RNA-binding proteins (RBPs) like HuR (ELAVL1) and tristetraprolin (TTP/ZFP36), as well as microRNAs such as miR-30e-3p. These interactions dictate the half-life of the mRNA and the efficiency of its translation into the pro-IL-1 beta protein. In many chronic inflammatory and autoinflammatory diseases, the dysregulation of these post-transcriptional mechanisms leads to the overproduction of IL-1 beta, driving pathological inflammation. Consequently, the IL1B mRNA 3'-UTR has emerged as a therapeutic target for antisense oligonucleotides (ASOs) and small molecules designed to destabilize the transcript or block its translation. By specifically targeting the mRNA rather than the mature protein or its receptor, these therapies aim to provide a more precise modulation of the IL-1 signaling pathway. This approach is particularly relevant for patients who are refractory to traditional IL-1 blockers like anakinra or canakinumab.

Other names
IL-1 beta mRNA 3'-UTRInterleukin-1 beta 3'-untranslated regionIL1B 3'-UTRIL1B 3' untranslated region
02

Mechanism of action

Modulation of mRNA stability and translation through binding to regulatory elements (e.g., AU-rich elements) or microRNA binding sites, leading to mRNA degradation or translational repression.

03

Biological functions

Regulation of mRNA stabilityRegulation of translationPost-transcriptional regulationImmune response
04

Disease associations

InflammationAutoimmune diseaseAutoinflammatory syndromeCancerRheumatoid arthritisFamilial Mediterranean fever
05

Safety considerations

Off-target RNA bindingSystemic immunosuppressionInjection site reactions (for ASOs)Potential for cytokine release syndrome if dysregulated
06

Interacting drugs

Antisense oligonucleotides (ASOs)

2 more in the full profile.

07

Biomarkers

IL-1 beta protein levelsIL-1 beta mRNA levelsC-reactive protein (CRP)Pro-inflammatory cytokine profile

Beyond the preview

Go deeper on Interleukin 1 beta mRNA 3'-untranslated region (IL1B mRNA 3'-UTR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin 1 beta mRNA 3'-untranslated region (IL1B mRNA 3'-UTR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call